Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

#4613

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Aim(s): To evaluate serum tumour biomarkers levels in patients with PNENs, assess their diagnostic and prognostic utility, and explore their association with disease extent and grade.

Materials and methods: A total of 115 PNEN patients and 40 healthy controls (HC) were enrolled. Of the PNEN patients, 63 had localised disease, 8 regional and 44 distant metastases; the majority of PNEN patients had non-functional (93.91%) and well-differentiated (93.04%) disease. 60 were diagnosed with NET G1 (52.17%), 47 - G2 (40.87%), and 8 - G3 (6,96%). Serum levels of cytokeratin 18 (CY18), ferritin, cancer antigen 125 (CA125), and beta-2 microglobulin (BMG) were measured. ROC analysis was used to assess diagnostic accuracy, and Kruskal-Wallis tests were used to evaluate differences in biomarker levels by disease stage and grade.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,